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To the Editor: Recently, Axelsson et al.1 showed that
glomerular filtration rate was consistently associated with
serum resistin levels in patients with chronic kidney disease.
It was found that the significant relationship between plasma
resistin levels and insulin resistance was lost after adjustment
for glomerular filtration rate, leading to the conclusion that
renal function is an important factor to take into account
when relating insulin sensitivity to inflammatory biomarkers
in patients with kidney disease or diabetes mellitus. We have
data from a population-based cohort of 64-year-old women,
consisting of women with known and new diabetes (diabetes
mellitus, n¼ 229), impaired glucose tolerance (n¼ 210), and
normal glucose tolerance (n¼ 191).2 Diabetes mellitus,
impaired glucose tolerance, and normal glucose tolerance
were defined according to the World Health Organization
classification. The serum levels of resistin were measured with
an enzyme-linked immunosorbent assay kit (R&D Systems
Europe, Abingdon, UK). The characteristics of the subjects
are presented in Table 1. Serum creatinine did not differ
between the groups and correlated positively to serum
resistin (Spearman’s correlation coefficients 0.36 (Po0.01),
0.28 (Po0.01), and 0.15 (Po0.05) for the diabetes mellitus,
impaired glucose tolerance, and normal glucose tolerance
groups, respectively). In a multivariate analysis, serum
creatinine remained associated with resistin after adjustment
for C-reactive protein, white blood cell count, high-density
lipoprotein cholesterol, body mass index, glucose tolerance
group, and plasma insulin (partial correlation coefficient
0.33, Po0.001). These data indicate that the association
between glomerular filtration rate and serum resistin also
represents a physiological mechanism that not necessarily is
linked to kidney disease.
1. Axelsson J, Bergsten A, Qureshi AR et al. Elevated resistin levels in chronic
kidney disease are associated with decreased glomerular filtration rate
and inflammation, but not with insulin resistance. Kidney Int 2006; 69:
596–604.
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To the Editor: Similarly to the article by Axelsson et al.1
entitled ‘Elevated resistin levels in chronic kidney disease are
associated with decreased glomerular filtration rate and
inflammation, but not with insulin resistance’ we have
recently observed in 33 non-diabetic hemodialysis patients
that elevated resistin plasma levels are not associated with
insulin resistance. In addition, we detected for the first time
in human subjects that resistin levels are inversely correlated
with the protein catabolic rate (r¼0.416, P¼ 0.025), which
is known to parallel the dietary protein uptake (Figure 1).2
Axelsson et al.1 have not reported on this important aspect in
their manuscript despite the high prevalence of protein and
energy malnutrition in hemodialysis patients and in patients
with chronic kidney disease.
The finding by Axelsson et al.1 that plasma resistin levels
are strongly correlated with inflammatory markers and
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Table 1 | Characteristics of the subjects (geometric
means7s.d.) (n=630)
DM
(n=229)
IGT
(n=210)
NGT
(n=191)
Serum resistin (ng/ml) 10.873.6 10.273.7 9.973.2**
Serum creatinine (mmol/l) 89714 89711 89710
BMI (kg/m2) 28.874.9 27.175.0 25.873.5*
Blood glucose (mmol/l) 7.172.8 5.070.6 4.770.5*
Serum HDL cholesterol (mmol/l) 1.4570.43 1.5670.42 1.7470.42*
White blood cell count ( 10*9/l ) 6.671.8 6.171.8 5.671.5*
C-reactive protein (mg/l) 1.9710.3 1.373.7 1.372.5*
Abbreviations: BMI, body mass index; DM, diabetes mellitus; HDL, high-density
lipoprotein; IGT, impaired glucose tolerance; NGT, normal glucose tolerance; s.d.,
standard deviation.
*Po0.001; **P=0.006.
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Figure 1 | Hemodialysis patients (n¼ 33) were divided into three
groups of 11 patients each according to the protein catabolic
rate. The patients with the lowest protein catabolic rate exhibited
the highest resistin levels. These intergroup differences are
statistically significant (Po0.05).
Kidney International (2006) 70, 1371–1384 1371
independent from glomerular filtration rates is of consider-
able interest, as elevated resistin levels in various other
disorders have been associated with both inflammation as
well as malnutrition.3–5
Taking into account that inflammation has been closely
related to malnutrition and in particular to protein–energy
malnutrition,6 one may assume that there is a relationship
between inflammation, plasma resistin levels, and protein
malnutrition in hemodialysis patients and in patients with
chronic kidney disease that is yet to be clarified.
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Response to ‘Resistin letters’
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We thank Fagerberg et al. for their contribution to the
growing body of evidence refuting a causative relationship
between the protein resistin and insulin resistance in
man.1 Indeed, resistin was first described as found in
inflammatory zone (FIZZ)-1, indicating its structural
similarity to several other proinflammatory cytokines.2
Indeed, resistin is expressed mainly in immunocompetent
cells such as leukocytes, and not in adipocytes as had
previously been thought.3,4
Given the fact that even a mild renal function
impairment is associated with a chronic low-grade
inflammation5 and a markedly increased risk of cardio-
vascular death, it is not surprising that the patients in the
study of Fagerberg et al. displayed increased resistin levels
that were also correlated with serum creatinine, C-reactive
protein, and leukocyte counts.
Taken together, we believe that this study further
underscores the relationship between decreasing renal
function and increased risks of inflammation and cardio-
vascular disease. Resistin is one part of this complex, where
we are still looking for a unifying mechanism and an
effective therapy.
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Enlightenment on liver lanthanum
exposure
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To the Editor: Tissue lanthanum concentrations in the paper
by Slatopolsky et al.1 are similar to our own and others’
findings,2 but have been interpreted very differently.
Comparisons with ‘untreated’ controls are used to highlight
‘marked’ and ‘striking’ increases in deposition in nephrecto-
mized rats, including a 98-fold increase in liver concentra-
tion. When the appropriate comparator is used (lanthanum-
treated rats with normal renal function), there is no statistical
increase in bone and kidney concentrations in the uremic
animals, and only two- to three-fold higher liver concentra-
tions after 15 weeks of treatment. This is entirely consistent
with the absence of any effect of renal failure on systemic
lanthanum exposure3 and a small (two- to three-fold)
increase in first-pass liver exposure, as reported recently for
this uremic model.2 Although tissue concentrations increased
over time (termed ‘progressive accumulation’), their study
was too short to fully reflect the tissue kinetics of lanthanum,
and longer-term studies suggest achievement of steady-state
conditions (Figure 1). Although a maximal dose of
lanthanum (3% (w/w) of diet, 15–22 times the human dose
of 3 g/day)1 was administered for as long as practicable in a
nephrectomized model (limited by death owing to renal
failure), lanthanum concentrations were still only at trace
levels (o3 p.p.m.). As the natural liver concentrations of
other lysosomally transported metals such as iron and copper
are up to 2007 and 55 p.p.m., respectively,4 there would
1372 Kidney International (2006) 70, 1371–1384
l e t t e r t o t h e e d i t o r
